JP7551056B2 - プログラマブルなポリマー薬物 - Google Patents

プログラマブルなポリマー薬物 Download PDF

Info

Publication number
JP7551056B2
JP7551056B2 JP2020512429A JP2020512429A JP7551056B2 JP 7551056 B2 JP7551056 B2 JP 7551056B2 JP 2020512429 A JP2020512429 A JP 2020512429A JP 2020512429 A JP2020512429 A JP 2020512429A JP 7551056 B2 JP7551056 B2 JP 7551056B2
Authority
JP
Japan
Prior art keywords
occurrence
independently
compound
compounds
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020512429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536847A5 (enExample
JP2020536847A (ja
Inventor
トレイシー マトライ
シャラット シン
シー フレデリック バットレル
マイケル ヴァンブラント
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sony Corp
Sony Group Corp
Original Assignee
Sony Corp
Sony Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sony Corp, Sony Group Corp filed Critical Sony Corp
Publication of JP2020536847A publication Critical patent/JP2020536847A/ja
Publication of JP2020536847A5 publication Critical patent/JP2020536847A5/ja
Priority to JP2024152064A priority Critical patent/JP2025000634A/ja
Application granted granted Critical
Publication of JP7551056B2 publication Critical patent/JP7551056B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/605—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C08G79/02—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing phosphorus
    • C08G79/04—Phosphorus linked to oxygen or to oxygen and carbon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020512429A 2017-10-05 2018-10-05 プログラマブルなポリマー薬物 Active JP7551056B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024152064A JP2025000634A (ja) 2017-10-05 2024-09-04 プログラマブルなポリマー薬物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762568706P 2017-10-05 2017-10-05
US62/568,706 2017-10-05
PCT/US2018/054725 WO2019071208A1 (en) 2017-10-05 2018-10-05 PROGRAMMABLE POLYMERIC MEDICAMENTS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024152064A Division JP2025000634A (ja) 2017-10-05 2024-09-04 プログラマブルなポリマー薬物

Publications (3)

Publication Number Publication Date
JP2020536847A JP2020536847A (ja) 2020-12-17
JP2020536847A5 JP2020536847A5 (enExample) 2021-11-18
JP7551056B2 true JP7551056B2 (ja) 2024-09-17

Family

ID=64049721

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512429A Active JP7551056B2 (ja) 2017-10-05 2018-10-05 プログラマブルなポリマー薬物
JP2024152064A Pending JP2025000634A (ja) 2017-10-05 2024-09-04 プログラマブルなポリマー薬物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024152064A Pending JP2025000634A (ja) 2017-10-05 2024-09-04 プログラマブルなポリマー薬物

Country Status (6)

Country Link
US (4) US12145956B2 (enExample)
EP (1) EP3691690B1 (enExample)
JP (2) JP7551056B2 (enExample)
KR (1) KR20200067132A (enExample)
CN (1) CN111315415A (enExample)
WO (1) WO2019071208A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101847748B1 (ko) 2013-08-22 2018-04-10 소니 주식회사 수용성 형광 또는 유색 염료 및 그의 사용 방법
CN107454903B (zh) 2015-02-26 2021-01-01 索尼公司 包含共轭基团的水溶性荧光或着色染料
US11084932B2 (en) 2015-02-26 2021-08-10 Sony Group Corporation Phenylethynylnaphthalene dyes and methods for their use
JP6849599B2 (ja) 2015-05-11 2021-03-24 ソニー株式会社 超明色ダイマーまたはポリマー染料
WO2017173348A1 (en) 2016-04-01 2017-10-05 Sony Corporation Ultra bright dimeric or polymeric dyes with rigid spacing groups
CA3018564C (en) 2016-04-01 2024-04-23 Sony Corporation Ultra bright dimeric or polymeric fluorescent and colored dyes
US9851359B2 (en) 2016-04-06 2017-12-26 Sony Corporation Of America Ultra bright dimeric or polymeric dyes with spacing linker groups
EP3455299B1 (en) 2016-05-10 2024-01-17 Sony Group Corporation Compositions comprising a polymeric dye and a cyclodextrin and uses thereof
WO2017196954A1 (en) 2016-05-10 2017-11-16 Sony Corporation Ultra bright polymeric dyes with peptide backbones
CN109071961B (zh) 2016-05-11 2021-04-27 索尼公司 超亮二聚或聚合染料
JP7068191B2 (ja) 2016-06-06 2022-05-16 ソニーグループ株式会社 蛍光または有色レポーター基を含むイオン性ポリマー
JP7312929B2 (ja) 2016-07-29 2023-07-24 ソニーグループ株式会社 超明色二量体またはポリマー色素およびその調製のための方法
CN111093711A (zh) 2017-10-05 2020-05-01 索尼公司 可编程的树枝状药物
EP3691690B1 (en) 2017-10-05 2024-08-14 Sony Group Corporation Programmable polymeric drugs
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
JP2021510698A (ja) 2018-01-12 2021-04-30 ソニー株式会社 生物学的に活性な化合物を含むホスホアルキルリボースポリマー
JP2021510696A (ja) 2018-01-12 2021-04-30 ソニー株式会社 生物学的に活性な化合物を含む剛性間隔基を有するポリマー
JP2021520423A (ja) 2018-03-19 2021-08-19 ソニーグループ株式会社 蛍光シグナルを増強するための二価金属の使用
JP7515786B2 (ja) 2018-03-21 2024-07-16 ソニーグループ株式会社 リンカー基を有するポリマータンデム色素
EP3775052B1 (en) 2018-03-30 2024-06-05 Becton, Dickinson and Company Water-soluble polymeric dyes having pendant chromophores
WO2020006285A1 (en) 2018-06-27 2020-01-02 Sony Corporation Polymeric dyes with linker groups comprising deoxyribose
CN113905766A (zh) * 2019-04-11 2022-01-07 索尼集团公司 可编程的聚合药物
EP3952916A1 (en) * 2019-04-11 2022-02-16 Sony Group Corporation Programmable polymeric drugs
CN120037399A (zh) * 2019-04-11 2025-05-27 索尼集团公司 可编程的聚合药物
KR102718543B1 (ko) 2019-09-26 2024-10-18 소니그룹주식회사 링커 그룹을 갖는 중합체성 탠덤 염료
WO2022125564A1 (en) 2020-12-07 2022-06-16 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
CN116917738A (zh) 2021-04-07 2023-10-20 贝克顿·迪金森公司 水溶性荧光聚合物染料
WO2025047686A1 (ja) * 2023-08-31 2025-03-06 富士フイルム株式会社 標的化薬物複合体及びこれを含む医薬、並びに、化合物
WO2025074178A1 (en) * 2023-10-03 2025-04-10 Sony Group Corporation Methods for preparing polymeric dyes with drug conjugates
WO2025177173A1 (en) * 2024-02-20 2025-08-28 Sony Group Corporation Polymers useful for conjugating to antibodies and therapeutic uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092386A1 (en) 2007-04-23 2010-04-15 David Segev System for delivering therapeutic agents into living cells and cells nuclei
US20130137755A1 (en) 2007-04-23 2013-05-30 Segev Laboratories Limited System for delivering therapeutic agents into living cells and cells nuclei
US20160039850A1 (en) 2007-04-23 2016-02-11 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
WO2016074093A1 (en) 2014-11-14 2016-05-19 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
US20160176903A1 (en) 2012-10-22 2016-06-23 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
JP2020536845A (ja) 2017-10-05 2020-12-17 ソニー株式会社 プログラマブルな樹枝状薬物

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450305A (en) 1982-10-25 1984-05-22 American Cyanamid Company Poly(ethyleneoxy)-substituted-9,10-bis(phenylethynyl)anthracenes
US4476229A (en) 1982-11-08 1984-10-09 Abbott Laboratories Substituted carboxyfluoresceins
SU1121931A1 (ru) 1983-01-10 1988-04-15 Институт Биологической Химии Ан Бсср Конъюгаты тиреоидных гормонов с альбумином дл выработки антител к тиреоидным гормонам у животных
EP0355864A3 (en) 1984-03-15 1991-09-18 Wako Pure Chemical Industries, Ltd. Method of quantitatively measuring an oxidative substance by using triphenyl methane type leuco compounds as coloring matter
JPH0665677B2 (ja) 1985-03-09 1994-08-24 三菱化成株式会社 リン脂質類似構造を有するジオ−ルおよびその製造方法
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US5053054A (en) 1988-09-12 1991-10-01 Ortho Pharmaceutical Corporation Methods and reagents for staining intracellular components
US5318894A (en) 1990-01-30 1994-06-07 Miles Inc. Composition, device and method of assaying for peroxidatively active substances
US6365730B1 (en) 1990-06-19 2002-04-02 Gene Shears Pty. Limited DNA-Armed ribozymes and minizymes
JPH04282391A (ja) 1991-03-08 1992-10-07 Fujisawa Pharmaceut Co Ltd エタノールアミン誘導体およびその製造法
US5698391A (en) 1991-08-23 1997-12-16 Isis Pharmaceuticals, Inc. Methods for synthetic unrandomization of oligomer fragments
ATE152831T1 (de) 1991-09-16 1997-05-15 Molecular Probes Inc Dimere unsymmetrische cyaninfarbstoffe
ES2159282T3 (es) 1991-11-07 2001-10-01 Nanotronics Inc Hibridacion de polinucleotidos conjugados con cromoforas y fluoroforos con el fin de generar sistemas de transferencia de energia de donador a donador.
DE69429338T2 (de) 1993-04-13 2002-08-14 Naxcor, Menlo Park Nicht-nucleosidische cumarin-derivate als reagenzien zum crosslinking von polynucleotiden
WO1995002700A1 (en) 1993-07-13 1995-01-26 Abbott Laboratories Fluorescent polymer labeled conjugates and intermediates
WO1995006731A2 (en) 1993-09-02 1995-03-09 Ribozyme Pharmaceuticals, Inc. Non-nucleotide containing enzymatic nucleic acid
US5886177A (en) 1994-01-11 1999-03-23 Isis Pharmaceuticals, Inc. Phosphate linked oligomers
US6171859B1 (en) 1994-03-30 2001-01-09 Mitokor Method of targeting conjugate molecules to mitochondria
US5994143A (en) 1996-02-01 1999-11-30 Abbott Laboratories Polymeric fluorophores enhanced by moieties providing a hydrophobic and conformationally restrictive microenvironment
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
DE19633268A1 (de) 1996-08-19 1998-02-26 Hoechst Ag Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung
JP2001511128A (ja) 1997-01-28 2001-08-07 ファルマシア・アンド・アップジョン・カンパニー 水不溶性ポルフィリンの脂質錯体の凍結乾燥物
US6893868B2 (en) 1997-02-20 2005-05-17 Onco Immunin, Inc. Homo-doubly labeled compositions for the detection of enzyme activity in biological samples
US5986030A (en) 1997-04-15 1999-11-16 Nalco Chemical Company Fluorescent water soluble polymers
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
JP3078793B2 (ja) 1998-04-30 2000-08-21 株式会社分子バイオホトニクス研究所 ロタキサン構造を有する色素、ラベル化剤、およびラベル化方法
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6514700B1 (en) 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US20020142329A1 (en) 1999-04-30 2002-10-03 Aclara Biosciences, Inc. Compositions and methods employing cleavable electrophoretic tag reagents
US7037654B2 (en) 1999-04-30 2006-05-02 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
AU5935300A (en) 1999-07-22 2001-02-13 Nalco Chemical Company Fluorescent water-soluble polymers
US6479650B1 (en) 1999-12-14 2002-11-12 Research Corporation Technologies, Inc. Fluorescent nucleoside analogs and combinatorial fluorophore arrays comprising same
AU2001245643A1 (en) 2000-03-14 2001-09-24 Genigma Corporation Biomarkers for the labeling, visual detection and quantification of biomolecules
AU2001255203A1 (en) 2000-03-28 2001-10-08 Nanosphere Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US20040067498A1 (en) 2000-04-28 2004-04-08 Ahmed Chenna Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
CA2409512A1 (en) 2000-05-08 2001-11-15 Qtl Biosystems Llc Improvements to the fluorescent polymer-qtl approach to biosensing
AU2001265252A1 (en) 2000-05-31 2001-12-11 The Johns-Hopkins University Biologically useful polyphosphates
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
AU8911101A (en) 2000-09-11 2002-03-26 Univ Columbia Combinatorial fluorescence energy transfer tags and uses thereof
WO2002024815A1 (en) 2000-09-19 2002-03-28 Li-Cor, Inc. Cyanine dyes
US6448407B1 (en) 2000-11-01 2002-09-10 Pe Corporation (Ny) Atropisomers of asymmetric xanthene fluorescent dyes and methods of DNA sequencing and fragment analysis
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
GB2372256A (en) 2001-02-14 2002-08-21 Kalibrant Ltd Detectable entity comprising a plurality of detectable units releasably connected together by stimulus-cleavable linkers for use in fluorescence detection
US6743905B2 (en) 2001-04-16 2004-06-01 Applera Corporation Mobility-modified nucleobase polymers and methods of using same
US8323903B2 (en) 2001-10-12 2012-12-04 Life Technologies Corporation Antibody complexes and methods for immunolabeling
JP3813890B2 (ja) 2002-03-22 2006-08-23 富士写真フイルム株式会社 ３層レジストプロセス用中間層材料組成物及びそれを用いたパターン形成方法
US20040086914A1 (en) 2002-07-12 2004-05-06 Affymetrix, Inc. Nucleic acid labeling methods
WO2004019002A2 (en) 2002-08-23 2004-03-04 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent glycosides and methods for their use
CA2497152C (en) 2002-08-26 2016-06-07 The Regents Of The University Of California Methods and compositions for detection and analysis of polynucleotides using light harvesting multichromophores
US20040138467A1 (en) 2002-11-26 2004-07-15 French Roger Harquail Aromatic and aromatic/heteroaromatic molecular structures with controllable electron conducting properties
WO2004062475A2 (en) 2003-01-10 2004-07-29 Albert Einstein College Of Medicine Of Yeshiva University Fluorescent assays for protein kinases
US7238792B2 (en) 2003-03-18 2007-07-03 Washington State University Research Foundation Foldable polymers as probes
US7172907B2 (en) 2003-03-21 2007-02-06 Ge Healthcare Bio-Sciences Corp. Cyanine dye labelling reagents with meso-substitution
US7544664B2 (en) 2003-08-14 2009-06-09 Diatos, S.A. Sequences facilitating penetration of a substance of interest
US7667024B2 (en) 2003-11-19 2010-02-23 Allelogic Biosciences Corp. Oligonucleotides labeled with a plurality of fluorophores
WO2005064336A1 (en) 2003-12-09 2005-07-14 Molecular Probes, Inc. Pyrenyloxysulfonic acid fluorescent agents
EP1768998A2 (en) 2004-04-27 2007-04-04 Alnylam Pharmaceuticals Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
US20060035302A1 (en) 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
US7671218B2 (en) 2004-08-13 2010-03-02 Elitech Holdings B.V. Phosphonate fluorescent dyes and conjugates
WO2006031851A1 (en) 2004-09-14 2006-03-23 Applera Corporation Multi-chromophoric quencher constructs for use in high sensitivity energy transfer probes
US8153706B2 (en) 2004-10-25 2012-04-10 Hewlett-Packard Development Company, L.P. Polymeric colorants having pigment and dye components and corresponding ink compositions
DE602004007007T2 (de) 2004-11-09 2008-02-21 Ipagsa Industrial, SL., Rubi Thermisch reaktive, nah-infrarot absorbierende Polymere und ihre Verwendung in wärmeempfindlichen lithographischen Druckplatten
CA2594458C (en) 2005-01-10 2016-08-23 The Regents Of The University Of California Cationic conjugated polymers suitable for strand-specific polynucleotide detection in homogeneous and solid state assays
AU2006223384B2 (en) 2005-03-09 2012-08-02 Cepheid Polar dyes
US8227621B2 (en) 2005-06-30 2012-07-24 Li-Cor, Inc. Cyanine dyes and methods of use
JP2009510198A (ja) 2005-09-26 2009-03-12 インヴィトロジェン コーポレーション 紫色レーザー励起性色素及びその使用方法
BRPI0618713B8 (pt) 2005-11-18 2021-07-27 The Government Of The United State Of America Representado Por The Secretary Of The Dept Of Health A cardiolipina modificada e seus usos
US8101776B2 (en) 2005-12-12 2012-01-24 Basf Se Organic semiconductors and their manufacture
US20070148094A1 (en) 2005-12-22 2007-06-28 Uzgiris Egidijus E Polymeric imaging agents and medical imaging methods
JP5493117B2 (ja) 2006-02-15 2014-05-14 国立大学法人岐阜大学 オリゴヌクレオチド誘導体及びその利用
EP2029120B1 (en) 2006-04-13 2011-07-27 Midatech Ltd. Nanoparticles containing three various ligands for providing immune responses against infectious agents
WO2008021208A2 (en) 2006-08-12 2008-02-21 Stx Aprilis, Inc. Sensitizer dyes for photoacid generating systems using short visible wavelengths
US8217389B2 (en) 2006-10-12 2012-07-10 Idemitsu Kosan, Co., Ltd. Organic thin film transistor device and organic thin film light-emitting transistor
EP2727965B1 (en) 2006-10-27 2019-03-06 Life Technologies Corporation FLUOROGENIC pH SENSITIVE DYES AND THEIR METHOD OF USE
US8053588B2 (en) 2007-03-07 2011-11-08 Kabushiki Kaisha Toyota Chuo Kenkyusho Organosilane compound and organosilica obtained therefrom
EP2155805A2 (en) 2007-05-11 2010-02-24 Basf Se Polymeric dyes
EP2014698A1 (en) 2007-07-12 2009-01-14 Crystax Pharmaceuticals S.L. Polymers and their use as fluorescent labels
TWI409280B (zh) 2007-07-31 2013-09-21 American Dye Source Inc 聚合物染料、塗覆層組合物及熱微影印刷板
GB2456298A (en) 2008-01-07 2009-07-15 Anthony Ian Newman Electroluminescent materials comprising oxidation resistant fluorenes
KR101564796B1 (ko) 2008-03-10 2015-10-30 고쿠리츠다이가쿠호우진 도쿄다이가쿠 비하전성 친수성 블록 및 측사슬의 일부에 소수성 기가 도입된 카티온성 폴리아미노산 블록을 포함하여 이루어지는 공중합체, 그 사용
CA2721980C (en) 2008-04-21 2017-01-03 The Regents Of The University Of California Selective high-affinity poly dentate ligands and methods of making such
KR101041446B1 (ko) 2008-07-21 2011-06-14 부산대학교 산학협력단 공액고분자 2단계 ｆｒｅｔ 시스템 및 바이오센서
JPWO2010026957A1 (ja) 2008-09-03 2012-02-02 国立大学法人富山大学 水溶性ロタキサン型蛍光色素および蛍光性有機分子
CA2738807A1 (en) * 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
US8354515B2 (en) 2008-11-14 2013-01-15 Japan Science And Technology Agency Oligonucleotide derivative, labeling agent and use for labeling agent
JP5798487B2 (ja) 2008-11-20 2015-10-21 ネーデルランドセ・オルガニサティ・フォール・トゥーヘパスト−ナトゥールウェテンスハッペライク・オンデルズーク・テーエヌオー Ｆｒｅｔに基づく病原体の迅速診断
EP2358770B1 (en) 2008-12-12 2017-03-15 University of Massachusetts Zwitterionic polymers with therapeutic moieties
US8846110B2 (en) * 2009-10-13 2014-09-30 Rexahn Pharmaceuticals, Inc. Polymeric systems for the delivery of anticancer drugs
CN106519588B (zh) 2009-11-09 2019-08-20 华盛顿大学商业化中心 官能化发色聚合物点及其生物共轭体
US9400273B1 (en) 2009-12-09 2016-07-26 Life Technologies Corporation 7-hydroxycoumarin-based cell-tracking reagents
US9221759B2 (en) 2010-01-13 2015-12-29 Rutgers, The State University Of New Jersey Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency
EP2545373B1 (en) 2010-03-11 2022-08-24 Medtronic Minimed, Inc. Measuring analyte concentration incorporating temperature and ph correction
JP2013528665A (ja) 2010-03-26 2013-07-11 メルサナ セラピューティックス， インコーポレイテッド ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法
EP2577309B1 (en) 2010-05-25 2016-11-23 Carnegie Mellon University Targeted probes of cellular physiology
CN102971283A (zh) 2010-07-08 2013-03-13 旭硝子株式会社 含氟芳香族化合物、有机半导体材料和有机薄膜器件
EP3170846A1 (en) 2010-09-22 2017-05-24 The Board of Regents of The University of Texas System Novel block copolymer and micelle compositions and methods of use thereof
CA3065178C (en) 2010-12-13 2022-02-01 Quiapeg Pharmaceuticals Ab Functionalized polymers
WO2012086857A1 (ko) 2010-12-21 2012-06-28 (주)파낙스이엠 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법
CN102174078A (zh) 2011-01-10 2011-09-07 中国药科大学 肿瘤细胞选择性穿膜肽的应用
CN103813809A (zh) * 2011-04-12 2014-05-21 波利艾克蒂瓦有限公司 聚合物缀合的前列腺素类似物
DK2769226T3 (en) 2011-07-15 2017-09-11 Medtronic Minimed Inc COMBINATIONS OF FLUORPHORES AND PYRIDINIUM BORIC ACID QUENCHERS FOR USE IN ANALYTICAL SENSORS
BR112014004544A2 (pt) 2011-08-31 2017-04-04 Mallinckrodt Llc modificação com peg de nanopartículas com h-fosfonatos
US20130059343A1 (en) 2011-09-06 2013-03-07 Li-Cor, Inc. Nucleotide derivatives
US9085761B1 (en) 2012-06-14 2015-07-21 Affymetrix, Inc. Methods and compositions for amplification of nucleic acids
JP6333244B2 (ja) * 2012-06-26 2018-05-30 ポリアクティヴァ・プロプライエタリー・リミテッド ポリマー−ｎｓａｉｄコンジュゲート
DK2895607T3 (da) 2012-09-12 2021-05-25 Quark Pharmaceuticals Inc Dobbeltstrengede oligonukleotidmolekyler til ddit4 og fremgangsmåder til anvendelse deraf
US20150258217A1 (en) 2012-10-04 2015-09-17 The General Hospital Corporation Methods of Synthesizing and Using Peg-Like Fluorochromes
WO2014102806A1 (en) 2012-12-31 2014-07-03 Yeda Research And Development Co. Ltd. Protein biosensors, cross reactive sensor arrays and methods of use thereof
US9545447B2 (en) 2013-01-04 2017-01-17 The Texas A&M University System Polymer-drug systems
US9169256B2 (en) 2013-03-13 2015-10-27 Elitechgroup B.V. Artificial nucleic acids
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
CN105073761B (zh) 2013-03-15 2020-10-20 文森医学公司 用于体外和体内成像和检测的取代的硅杂蒽阳离子红至近红外荧光染料
WO2014147642A1 (en) 2013-03-19 2014-09-25 Council Of Scientific & Industrial Research Substituted fluoranthene-7-carbonitriles as fluorescent dyes for cell imaging applications
CN103319378B (zh) 2013-06-27 2015-06-10 中国科学院宁波材料技术与工程研究所 两性离子有机小分子太阳能电池阴极界面材料及其制法和用途
KR101572901B1 (ko) 2013-07-12 2015-12-15 부산대학교 산학협력단 2-단계 fret를 이용한 공액고분자 전해질 및 압타머 프로브 기반 표적 물질의 검출 방법 및 형광 센서
KR101847748B1 (ko) 2013-08-22 2018-04-10 소니 주식회사 수용성 형광 또는 유색 염료 및 그의 사용 방법
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
JP5802865B1 (ja) 2013-11-11 2015-11-04 オリンパス株式会社 処置システム
US9150782B2 (en) 2013-12-06 2015-10-06 Monosol, Llc Fluorescent tracer for water-soluble films, related methods, and related articles
CA2929972C (en) 2013-12-20 2018-07-24 F. Hoffmann-La Roche Ag Use of compounds comprising two or more hydrophobic domains and a hydrophilic domain comprising peg moieties for stabilization of a cell
KR101829159B1 (ko) 2014-01-16 2018-02-13 소니 주식회사 수용성 형광 또는 유색 염료
JP6374172B2 (ja) 2014-01-31 2018-08-15 富士フイルム株式会社 着色組成物、およびこれを用いた硬化膜、カラーフィルタ、パターン形成方法、カラーフィルタの製造方法、固体撮像素子、画像表示装置ならびに染料多量体
CN104072727A (zh) 2014-06-23 2014-10-01 华南理工大学 一种含磷脂酰胆碱基的2,7-芴的共轭聚合物及其制备方法与应用
WO2016055907A1 (en) * 2014-10-10 2016-04-14 Pfizer Inc. Synergistic auristatin combinations
WO2016077625A1 (en) 2014-11-12 2016-05-19 Stayton Patrick S Stabilized polymeric carriers for therapeutic agent delivery
DK178808B1 (en) 2014-12-12 2017-02-13 Envision Energy Denmark Aps Floating wind turbine structure with reduced tower height and method for optimising the weight thereof
CN107454903B (zh) 2015-02-26 2021-01-01 索尼公司 包含共轭基团的水溶性荧光或着色染料
US11084932B2 (en) 2015-02-26 2021-08-10 Sony Group Corporation Phenylethynylnaphthalene dyes and methods for their use
EP3268435B1 (en) 2015-03-12 2022-07-13 Becton, Dickinson and Company Polymeric bodipy dyes and methods for using the same
JP6849599B2 (ja) 2015-05-11 2021-03-24 ソニー株式会社 超明色ダイマーまたはポリマー染料
US9670318B2 (en) 2015-05-28 2017-06-06 Miltenyi Biotec Gmbh Bright fluorochromes based on multimerization of fluorescent dyes
JP6997455B2 (ja) 2015-06-02 2022-01-17 ユニバーシティ・オブ・ワシントン 自立非汚染性ポリマー、それらの組成物、および関連モノマー
CN115300640A (zh) 2015-08-10 2022-11-08 杭州多禧生物科技有限公司 新型连接体及其用于药物和生物分子的特异性偶联
US11510993B2 (en) 2015-10-06 2022-11-29 Merck Sharp & Dohme Llc Antibody drug conjugate for anti-inflammatory applications
HRP20240795T1 (hr) 2015-11-25 2024-09-13 Ligachem Biosciences Inc. Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
JP6841430B2 (ja) 2015-12-04 2021-03-10 全薬工業株式会社 血中滞留性を改善した抗ｉｌ−１７アプタマー
US9913992B2 (en) 2015-12-22 2018-03-13 Colgate-Palmolive Company Oral treatment device
JP2017124994A (ja) 2016-01-15 2017-07-20 靖彦 中村 癌治療及び癌再発防止のための装置並びにポルフィリン類含有製剤
CA3018564C (en) 2016-04-01 2024-04-23 Sony Corporation Ultra bright dimeric or polymeric fluorescent and colored dyes
WO2017173348A1 (en) 2016-04-01 2017-10-05 Sony Corporation Ultra bright dimeric or polymeric dyes with rigid spacing groups
US10901940B2 (en) 2016-04-02 2021-01-26 Intel Corporation Processors, methods, systems, and instructions to atomically store to memory data wider than a natively supported data width
US9851359B2 (en) 2016-04-06 2017-12-26 Sony Corporation Of America Ultra bright dimeric or polymeric dyes with spacing linker groups
WO2017196954A1 (en) 2016-05-10 2017-11-16 Sony Corporation Ultra bright polymeric dyes with peptide backbones
EP3455299B1 (en) 2016-05-10 2024-01-17 Sony Group Corporation Compositions comprising a polymeric dye and a cyclodextrin and uses thereof
CN109071961B (zh) 2016-05-11 2021-04-27 索尼公司 超亮二聚或聚合染料
JP7068191B2 (ja) 2016-06-06 2022-05-16 ソニーグループ株式会社 蛍光または有色レポーター基を含むイオン性ポリマー
JP7312929B2 (ja) 2016-07-29 2023-07-24 ソニーグループ株式会社 超明色二量体またはポリマー色素およびその調製のための方法
EP4425179A3 (en) 2016-09-01 2024-12-11 Life Technologies Corporation Compositions and methods for enhanced fluorescence
GB2554666B (en) 2016-09-30 2019-12-18 Sumitomo Chemical Co Composite Particle
CN106589005B (zh) 2016-11-01 2019-08-06 北京擎科生物科技有限公司 一种荧光信号放大探针中间体、荧光探针及其制备方法
AU2018223809B2 (en) 2017-02-27 2022-12-15 Ivanti, Inc. Systems and methods for role-based computer security configurations
US12398104B2 (en) 2017-04-27 2025-08-26 The Procter & Gamble Company Odorless thiols for permanent waving, straightening and depilatory applications
JP7234151B2 (ja) 2017-07-07 2023-03-07 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 脂肪酸誘導体およびこれらの使用
EP3691690B1 (en) 2017-10-05 2024-08-14 Sony Group Corporation Programmable polymeric drugs
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
KR102773157B1 (ko) 2017-12-13 2025-02-27 소니그룹주식회사 생물학적 활성 화합물을 함유하는 이온성 중합체
TW201929908A (zh) 2017-12-21 2019-08-01 美商梅爾莎納醫療公司 吡咯并苯并二氮呯抗體共軛物
WO2019140128A1 (en) 2018-01-12 2019-07-18 Sony Corporation Phosphoalkyl polymers comprising biologically active compounds
JP2021510698A (ja) 2018-01-12 2021-04-30 ソニー株式会社 生物学的に活性な化合物を含むホスホアルキルリボースポリマー
JP2021510696A (ja) 2018-01-12 2021-04-30 ソニー株式会社 生物学的に活性な化合物を含む剛性間隔基を有するポリマー
JP2021520423A (ja) 2018-03-19 2021-08-19 ソニーグループ株式会社 蛍光シグナルを増強するための二価金属の使用
JP7515786B2 (ja) 2018-03-21 2024-07-16 ソニーグループ株式会社 リンカー基を有するポリマータンデム色素
GB201807815D0 (en) 2018-05-14 2018-06-27 Hypha Discovery Ltd Hydroxylation techniques
WO2020006285A1 (en) 2018-06-27 2020-01-02 Sony Corporation Polymeric dyes with linker groups comprising deoxyribose
US20210285953A1 (en) 2018-07-13 2021-09-16 Sony Corporation Polymeric dyes having a backbone comprising organophosphate units
EP3952916A1 (en) 2019-04-11 2022-02-16 Sony Group Corporation Programmable polymeric drugs
CN120037399A (zh) 2019-04-11 2025-05-27 索尼集团公司 可编程的聚合药物
CN113905766A (zh) 2019-04-11 2022-01-07 索尼集团公司 可编程的聚合药物
JP7650819B2 (ja) 2019-04-24 2025-03-25 ブイオーアール バイオファーマ インコーポレーテッド 抗－ｃｄ４５抗体薬物コンジュゲート及びその使用
KR102718543B1 (ko) 2019-09-26 2024-10-18 소니그룹주식회사 링커 그룹을 갖는 중합체성 탠덤 염료
WO2021067483A1 (en) 2019-09-30 2021-04-08 Sony Corporation Nucleotide probes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092386A1 (en) 2007-04-23 2010-04-15 David Segev System for delivering therapeutic agents into living cells and cells nuclei
US20130137755A1 (en) 2007-04-23 2013-05-30 Segev Laboratories Limited System for delivering therapeutic agents into living cells and cells nuclei
US20160039850A1 (en) 2007-04-23 2016-02-11 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
US20160176903A1 (en) 2012-10-22 2016-06-23 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
WO2016074093A1 (en) 2014-11-14 2016-05-19 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
JP2020536845A (ja) 2017-10-05 2020-12-17 ソニー株式会社 プログラマブルな樹枝状薬物

Also Published As

Publication number Publication date
US12098161B2 (en) 2024-09-24
US20220227794A1 (en) 2022-07-21
KR20200067132A (ko) 2020-06-11
US20250127910A1 (en) 2025-04-24
WO2019071208A1 (en) 2019-04-11
US20210032277A1 (en) 2021-02-04
US11312736B1 (en) 2022-04-26
JP2025000634A (ja) 2025-01-07
CN111315415A (zh) 2020-06-19
US12145956B2 (en) 2024-11-19
EP3691690B1 (en) 2024-08-14
JP2020536847A (ja) 2020-12-17
EP3691690A1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
JP7551056B2 (ja) プログラマブルなポリマー薬物
JP7515785B2 (ja) 生物学的に活性な化合物を含むホスホアルキルポリマー
JP7403744B2 (ja) プログラマブルな樹枝状薬物
US12194104B2 (en) Phosphoalkyl ribose polymers comprising biologically active compounds
US12076407B2 (en) Polymers with rigid spacing groups comprising biologically active compounds
JP2024050717A (ja) 生物学的に活性な化合物を含むイオン性ポリマー
US20210128739A1 (en) Programmable polymeric drugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230330

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240805

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240818

R150 Certificate of patent or registration of utility model

Ref document number: 7551056

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150